CC#14952: Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors

Sponsor: Merck and Co., Inc.

Location(s): United States


This study will assess the efficacy and safety of pembrolizumab administered to participants with incurable advanced biomarker-positive solid tumors that have not responded to current therapy or for which current therapy is not appropriate. The hypothesis is that administration of pembrolizumab to participants with some types of solid tumors will result in a clinically meaningful response rate.